See the DrugPatentWatch profile for fostamatinib
When will fostamatinib be generic?
Fostamatinib (Tavalisse) is still under patent and exclusivity protections, so a generic launch timing depends on when those protections expire and whether they’re challenged in court. The provided information doesn’t include the relevant patent or exclusivity dates, so there isn’t enough data here to give a reliable “generic available by” timeline.
What dates determine when a generic of fostamatinib can launch?
Generic entry is usually driven by:
- Patent expiry for the active ingredient and key drug-related patents
- Regulatory exclusivities (such as periods tied to FDA approval)
- Patent litigation outcomes that can delay approval or launch
Specific dates are not included in the information provided, so the exact timing can’t be calculated.
Can a generic be approved before it launches?
Yes. In many cases, a generic manufacturer can receive FDA approval before the drug can be marketed, but the launch date can still be blocked by unexpired patents and exclusivity. The exact scenario for fostamatinib depends on the status of the patents and any legal settlements or court rulings, which aren’t provided here.
What should you check to find the expected generic launch date?
To determine when fostamatinib will likely become generic, look up:
- FDA Orange Book listings for fostamatinib (patent and exclusivity expiration dates)
- Any ongoing or completed patent litigation affecting launch timing
- Country-specific regulatory approvals (US vs. EU vs. UK can differ)
If you share your country (e.g., US or UK) and whether you mean “generic approved” or “generic on pharmacy shelves,” I can narrow what to look for—but the actual expiration dates still need to come from a source that lists them.